Arcutis Biotherapeutics
ARQT
283 hedge funds and large institutions have $3.75B invested in Arcutis Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 74 funds opening new positions, 103 increasing their positions, 77 reducing their positions, and 25 closing their positions.
712% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $2.6M
196% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 25
58% more capital invested
Capital invested by funds: $2.37B → $3.75B (+$1.38B)
34% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 77
18% more funds holding
Funds holding: 239 → 283 (+44)
0.63% more ownership
Funds ownership: 104.93% → 105.56% (+0.63%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$38M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$37.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$27.6M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$23M |
| 5 |
State Street
Boston,
Massachusetts
|
+$21.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$141M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$63.4M |
| 3 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
-$28.5M |
| 4 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$19.3M |
| 5 |
Janus Henderson Group
London,
|
-$14.5M |
ARQT Hedge Fund Activity: Q4 2025 in Review
283 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q4 2025, worth a combined $3.75B — up 58% from $2.37B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new ARQT positions and 25 closed out — a net gain of 49 holders — while 103 added to existing stakes and 77 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $38M. The largest seller was Jennison Associates, cutting an estimated $141M.
- 283 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q4 2025, up from 239 in Q3 2025.
- Funds reported $3.75B of Arcutis Biotherapeutics stock for Q4 2025, up 58% quarter-over-quarter.
- 74 funds opened new Arcutis Biotherapeutics positions in Q4 2025 and 25 closed out, a net change of +49 holders.
- The largest Arcutis Biotherapeutics buyer in Q4 2025 was Suvretta Capital Management, an estimated $38M added.
- The largest Arcutis Biotherapeutics seller in Q4 2025 was Jennison Associates, an estimated $141M sold.
Based on aggregated 13F filings for Q4 2025.